# CJC-1295 / Ipamorelin: Research Overview — LKN Peptide > A literature summary of CJC-1295 combined with Ipamorelin — a GHRH analogue paired with a selective ghrelin-receptor agonist studied for endogenous growth-hormone support. Covers mechanism, single-agent trial data, and cited safety cautions. A long-acting GHRH analogue paired with a selective ghrelin-receptor agonist, reasoned to produce a bigger growth-hormone pulse than either alone — a mechanism with real receptor-level support, and a fixed combination that has never itself been tested in a controlled human trial. ## The short version CJC-1295 and ipamorelin are two different research peptides that are frequently used together as a pair, or 'stack.' CJC-1295 is a modified version of a fragment of growth hormone-releasing hormone (GHRH) — the natural signal that tells the pituitary gland to release growth hormone (GH). A modified 'DAC' version of CJC-1295 sticks to a blood protein called albumin, which is thought to make its effect last for days instead of hours. Ipamorelin works through a completely different switch: it mimics the hunger hormone ghrelin, docking onto a separate receptor (called GHS-R1a) that also triggers GH release. Because the two peptides act through separate pathways on the same pituitary cell, cell-based lab work suggests combining them produces a bigger GH signal than either one gets alone. That is a real, tested mechanism — but no controlled study has ever tested the fixed CJC-1295 + ipamorelin combination itself in people. This page separates what is known about each half from what is only inferred about the pair. ## What it is CJC-1295 is a tetra-substituted analogue of the amino-terminal 1-29 fragment of human growth hormone-releasing hormone (hGRF(1-29)NH2). Its 'with DAC' (Drug Affinity Complex) form adds a C-terminal N-epsilon-maleimidopropionamide-lysine group that covalently bonds to the Cys34 thiol of circulating serum albumin, sharply extending the peptide's residence time in the body; the 'no-DAC' form (sometimes called Mod GRF (1-29)) omits that modification and clears far faster. Ipamorelin is a much smaller synthetic pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — engineered to be a selective agonist at GHS-R1a, the receptor that also responds to the hunger hormone ghrelin, while avoiding the broader hormone-release effects seen with older, less selective secretagogues. ## How it works CJC-1295 binds the GHRH receptor, a class-B G-protein-coupled receptor on pituitary somatotroph cells, activating the Gs/adenylyl cyclase/cAMP pathway to drive GH synthesis and release; the DAC-bound form's albumin attachment is what stretches that signal out over days rather than hours. Ipamorelin instead binds GHS-R1a on the same somatotroph cells, raising intracellular calcium through a Gq-coupled pathway — a mechanistically distinct route to the same outcome. Because the two receptors converge on GH release through separate second-messenger systems, co-activating both is intended to produce a supra-additive pulse rather than a simple sum of two smaller ones. Direct cell-level evidence supports this: co-activating cloned GHRH and GHS receptors in transfected cells produced roughly double the cAMP response of GHRH-receptor activation alone [5]. ## What the research shows *Read-across from the GHRH-analogue class.* A 2026 meta-analysis of five randomized controlled trials of tesamorelin — a related long-acting GHRH analogue also covered on this desk — found significant reductions in visceral adipose tissue (mean difference -27.71 cm2) and liver fat (-4.28%), along with increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose disruption [1]. This is not a CJC-1295 trial, but it is the best available evidence for what sustained GHRH-receptor stimulation does to body composition under controlled conditions. *Class-level safety.* A review of growth-hormone secretagogues broadly found them generally well tolerated, with the main safety signal being modestly increased blood glucose from reduced insulin sensitivity, and noted that long-term data on cancer incidence and mortality are still needed [2]. *CJC-1295 itself.* In healthy adults, a single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH two- to ten-fold for six or more days and IGF-1 by 1.5- to 3-fold for nine to eleven days; with repeated dosing, IGF-1 stayed above baseline for up to 28 days [3]. In rats, the DAC chemistry that lets CJC-1295 bind albumin produced roughly a four-fold increase in GH exposure over two hours compared with unmodified hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours [4]. *Receptor synergy.* Co-activating cloned GHRH and ghrelin (GHS) receptors in transfected cells produced about double the cAMP response of GHRH-receptor activation alone — the clearest mechanistic evidence for why the two peptides are paired [5]. ## Reported effects, cautions & safety People using the CJC-1295 + ipamorelin combination in research-use communities describe a fairly consistent set of effects. *This section is anecdotal, not clinical evidence* — it is compiled from online community reports, not controlled studies, and no dose or source can be verified. *Reported benefits:* Deeper, more restorative sleep is the single most frequently mentioned effect, often noticed within one to two weeks. Faster workout recovery and less next-day soreness are also commonly described, frequently discussed alongside other recovery-focused peptides. A smaller number of users report gradual fat loss over five or more weeks (heavily confounded by concurrent diet and training changes), an uptick in appetite shortly after dosing — a plausible extension of ipamorelin's ghrelin-receptor activity — and, less consistently, improved skin, hair, or general mood. *Reported adverse effects:* Injection-site redness, itching, or mild swelling is the most common complaint. Some users describe transient water retention or puffiness, a brief facial flush or head-rush in the minutes after dosing, occasional tingling or numbness in the hands, or grogginess and lightheadedness, most often early in use. *Cited cautions from the literature:* Because GH and IGF-1 are mitogenic — meaning they promote cell growth and survival — chronically elevating them raises a theoretical concern for people with active or recent malignancy; CJC-1295 alone is documented to raise GH two- to ten-fold and IGF-1 for over a week after a single dose [3]. The GH-secretagogue class carries a documented glucose-tolerance concern that would matter most for people with diabetes or insulin resistance [2]. And the fixed blend itself remains untested: its two halves have mismatched pharmacokinetics — CJC-1295 DAC lasts days, ipamorelin clears in hours — so the actual GH exposure produced by any specific protocol has never been characterized in a controlled study [3][4]. ## Where it fits in Growth Hormone Axis CJC-1295/Ipamorelin is the most mechanistically ambitious and the least clinically tested compound on this desk. Where [sermorelin](/sermorelin) works through a single, well-characterized physiologic pathway and [tesamorelin](/tesamorelin) has an actual FDA-approved indication behind it, the CJC-1295 + ipamorelin combination is reasoned entirely from separate single-agent studies and a receptor-level synergy experiment [5] — a real mechanism, but one that has never been tested as the product is actually used. Reading it alongside the other two on this desk is the only way to see how much of its story is established pharmacology and how much is inference. See the [comparison page](/compare) for the side-by-side. ![CJC-1295 / Ipamorelin research illustration — abstract dual-receptor endocrine signaling motifs](/images/cjc1295-ipamorelin.webp) --- LKN Peptide pairs every enthusiastic finding about the growth-hormone axis with its citation and its caveat in the same breath — a research digest, not a clinic and not a supplier.